QuidelOrtho

QDEL

Market cap $1.78B

QDEL boosts its respiratory testing lineup with the FDA-cleared QUICKVUE Influenza + SARS Test for professional use.

SAN DIEGO , Sept. 25, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released the latest episode of its Science Bytes podcast, featuring Dr. Terry O'Neil, President and Medical Director of Urgent Care Pros.

SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of innovative in vitro diagnostic technologies, is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In QuidelOrtho (QDEL) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  QuidelOrtho between February 18, 2022 and April 1, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025. The Company's fireside chat will begin at 3:10 p.m.

SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the completion of a series of related transactions to refinance its debt structure and support future growth. Through these transactions, the Company extended its debt maturities and reduced required amortization payments.

SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, is sharing timely public health insights from Dr. Jonathan Temte, Professor of Family Medicine and Community Health at the University of Wisconsin-Madison. In this 50th episode of QuidelOrtho Science Bytes, Dr. Temte outlines the seasonal challenges posed by influenza, RSV, COVID-19 and vaccine-preventable diseases such as measles and whooping cough.

SAN DIEGO , Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr.

Initiative to expand testing access to underserved U.S. communities SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiative designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. Tailored for clinics, physician office labs and small hospitals with fewer than 100 beds, the program offers certified VITROS™ analyzers that deliver proven reliability and quality results, with award-winning service, at a fraction of the cost.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.